United States
|
|
| Product Center | |
 BBL™ CHROMagar™ MRSA |
|
| Cat. # | Desc. | Qty. | Unit |
| 215084 | BBL™ CHROMagar™ MRSA | 20 | SP |
| Product Image (select to enlarge) | |||||||||
 |
BBL™ CHROMagar™ MRSA is a selective and differential medium for the qualitative direct detection of nasal colonization by methicillin resistant Staphylococcus aureus (MRSA) to aid in the prevention and control of MRSA infections in healthcare settings. The test is performed on anterior nares swab specimens from patients and healthcare workers to screen for MRSA colonization. BBL CHROMagar MRSA is not intended to diagnose MRSA infection nor to guide or monitor treatment for infections.
| Catalog # | Description | Quantity | Unit |
| 215084 | BBL™ CHROMagar™ MRSA | 20 | SP |
BBL™ CHROMagar™ MRSA is a selective and differential medium for the qualitative direct detection of nasal colonization by methicillin resistant Staphylococcus aureus (MRSA) to aid in the prevention and control of MRSA infections in healthcare settings. The test is performed on anterior nares swab specimens from patients and healthcare workers to screen for MRSA colonization. BBL CHROMagar MRSA is not intended to diagnose MRSA infection nor to guide or monitor treatment for infections. BBL™ CHROMagar™ MRSA is a selective and differential medium for the qualitative direct detection of nasal colonization by methicillin resistant Staphylococcus aureus (MRSA) to aid in the prevention and control of MRSA infections in healthcare settings. The test is performed on anterior nares swab specimens from patients and healthcare workers to screen for MRSA colonization. BBL CHROMagar MRSA is not intended to diagnose MRSA infection nor to guide or monitor treatment for infections. MRSA are a major cause of nosocomial and life threatening infections. Infections with MRSA have been associated with a significantly higher morbidity, mortality and costs than methicillin-susceptible S. aureus (MSSA).1 Selection of these organisms has been greatest in the healthcare setting; however, MRSA have also become more prevalent in the community.2 To control the transmission of MRSA, the Society for Healthcare Epidemiology of America (SHEA) has recommended guidelines, which include an active surveillance program to identify potential reservoirs and a rigorous infection control program to control the spread of MRSA.1 BBL CHROMagar MRSA is a selective and differential medium, which incorporates cefoxitin, for the detection of MRSA from anterior nares specimens. BBL CHROMagar MRSA was developed by A. Rambach and BD. This product utilizes CHROMagar Staph aureus, which was developed by A. Rambach and is sold by BD under a licensing agreement with CHROMagar, Paris, France. MRSA are a major cause of nosocomial and life threatening infections. Infections with MRSA have been associated with a significantly higher morbidity, mortality and costs than methicillin-susceptible S. aureus (MSSA).1 Selection of these organisms has been greatest in the healthcare setting; however, MRSA have also become more prevalent in the community.2 To control the transmission of MRSA, the Society for Healthcare Epidemiology of America (SHEA) has recommended guidelines, which include an active surveillance program to identify potential reservoirs and a rigorous infection control program to control the spread of MRSA.1 BBL CHROMagar MRSA is a selective and differential medium, which incorporates cefoxitin, for the detection of MRSA from anterior nares specimens. BBL CHROMagar MRSA was developed by A. Rambach and BD. This product utilizes CHROMagar Staph aureus, which was developed by A. Rambach and is sold by BD under a licensing agreement with CHROMagar, Paris, France. Examine plates for signs of deterioration as described under "Product Deterioration." Check performance by inoculating a representative sample of plates with pure cultures of stable control organisms that produce known, desired reactions. S. aureus ATCC™ 25923 should be tested at a concentration of 104 - 105 CFU/plate10 to confirm the presence of cefoxitin. S. aureus ATCC 43300 should be tested at a concentration of 103 - 104 CFU/plate10 to determine the growth capacity of the medium and the performance of the chromogenic reaction.
Quality control requirements must be performed in accordance with applicable local, state and/or federal regulations or accreditation requirements and your laboratory's standard Quality Control procedures. It is recommended that the user refer to pertinent CLSI (formerly NCCLS) guidance and CLIA regulations for appropriate Quality Control practices.
For in vitro Diagnostic Use. Observe aseptic techniques and established precautions against microbiological hazards throughout all procedures. After use, prepared plates, specimen containers and other contaminated materials must be sterilized by autoclaving before discarding. Pathogenic microorganisms, including hepatitis viruses and Human Immunodeficiency Virus may be present in clinical specimens. "Standard Precautions"4-7 and institutional guidelines should be followed in handling all items contaminated with blood and other body fluids. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Information shown on this page is a short summary extracted from the Package Insert, available as a PDF under the Related Documents section of this page.
